Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Children With Neuroblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven neuroblastoma or maturing ganglioneuroma that is judged to be intermediate risk by one of the following criteria:~  * International Neuroblastoma Staging System (INSS) stage III~    * Under 1 year old, MYCN oncogene nonamplified, and any ploidy~   * 1 to 20 years old, MYCN nonamplified, favorable Shimada histology~ * INSS stage IV~    * Under 1 year old, MYCN nonamplified, any ploidy~ * INSS stage IVS~    * Under 1 year old, MYCN nonamplified, unfavorable Shimada histology and any ploidy OR favorable Shimada histology and diploidy~* All patients must be registered on the companion neuroblastoma biology study (COG-ANBL00B1)~PATIENT CHARACTERISTICS:~Age:~* Under 21~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~Other:~* No abnormal organ function that would prohibit chemotherapy unless due to neuroblastoma~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Prior chemotherapy for patients with intradural extension and emergent paresis allowed provided biopsy was performed within 96 hours after treatment~Endocrine therapy:~* Not specified~Radiotherapy:~* Not specified~Surgery:~* Not specified~Other:~* No other prior therapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): See detailed description.

Based on this trial design, predict the completion outcome and termination type (if applicable).